calcium/calmodulin-dependent protein kinase II beta
RGD ID:
2262
Description:
Enables calmodulin-dependent protein kinase activity; phospholipase binding activity; and protein kinase binding activity. A structural constituent of postsynaptic actin cytoskeleton. Involved in several processes, including cellular response to homocysteine; hippocampal neuron apoptotic process; and regulation of synapse organization. Acts upstream of or within long-term synaptic potentiation. Located in dendrite and perikaryon. Is active in glutamatergic synapse and postsynaptic density. Human ortholog(s) of this gene implicated in autosomal dominant intellectual developmental disorder 54. Orthologous to human CAMK2B (calcium/calmodulin dependent protein kinase II beta); PARTICIPATES IN calcium/calmodulin dependent kinase 2 signaling pathway; p38 MAPK signaling pathway; type II interferon signaling pathway; INTERACTS WITH (S)-amphetamine; 2,3,7,8-tetrachlorodibenzodioxine; 2,4,6-trinitrobenzenesulfonic acid.
Ca++/calmodulin-dependent protein kinase II beta subunit; Ca++/calmodulin-dependent protein kinase II, beta subunit; calcium/calmodulin-dependent protein kinase (CaM kinase) II beta; calcium/calmodulin-dependent protein kinase II beta subunit; calcium/calmodulin-dependent protein kinase II, beta; calcium/calmodulin-dependent protein kinase type II beta chain; calcium/calmodulin-dependent protein kinase type II subunit beta; caM kinase II subunit beta; caM-kinase II beta chain; caMK-II subunit beta; Ck2b
CAMK2B protein promotes the reaction [Tretinoin results in increased phosphorylation of MAPK1 protein] and CAMK2B protein promotes the reaction [Tretinoin results in increased phosphorylation of MAPK3 protein]
[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of CAMK2B mRNA
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of CAMK2B mRNA
[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of CAMK2B mRNA and [bisphenol A co-treated with tributyltin] results in increased expression of CAMK2B mRNA
[[Gasoline co-treated with 1-Butanol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CAMK2B mRNA
[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of CAMK2B mRNA
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of CAMK2B mRNA
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of CAMK2B mRNA
[Oxygen deficiency co-treated with Blood Glucose deficiency co-treated with Particulate Matter] results in increased expression of CAMK2B mRNA more ...
[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of CAMK2B mRNA
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of CAMK2B mRNA
[[Gasoline co-treated with Ethanol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CAMK2B mRNA
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of CAMK2B mRNA
[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of CAMK2B mRNA
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of CAMK2B mRNA
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of CAMK2B mRNA
[LDN 193189 co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide co-treated with EGF protein co-treated with FGF2 protein] results in increased expression of CAMK2B mRNA
tris(chloroethyl)phosphate results in increased expression of CAMK2B mRNA and tris(chloroethyl)phosphate results in increased expression of CAMK2B protein
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of CAMK2B mRNA
Group VIA phospholipase A2 forms a signaling complex with the calcium/calmodulin-dependent protein kinase IIbeta expressed in pancreatic islet beta-cells.